InhaleRx Limited (AU:IRX) has released an update.
InhaleRx Ltd has announced the submission of their Investigational New Drug application for IRX616a to the FDA, marking a significant step towards addressing the treatment needs in pain management and mental health sectors, particularly Panic Disorder. This development follows a positive pre-IND meeting with the FDA and sets the stage for potential approval, demonstrating the company’s dedication to bringing innovative therapies to market. Investors are watching closely as InhaleRx aims to meet a high unmet medical demand and improve patient outcomes in mental health.
For further insights into AU:IRX stock, check out TipRanks’ Stock Analysis page.
